Experimental Neurobiology

Table 2Administration protocols of psychosis animal model of amphetamine, scopolamine, PCP/ketamine and LSD in rats and mice

Drug		Dose		Duration	Strain	Behavior test	Reference
Amphetamine	Sub-chronic and incremental dosage schedule	3 injections (06:00,12:00, and 18:00)/day for 6 days	Day 1 – 1 mg/kg, 2 mg/kg, and 3 mg/kg	90 day	Wistar rats	Amphetamine sensitization (1 mg/kg challenge)	[14]
			Day 2 – 4 mg/kg, 5 mg/kg, and 5 mg/kg
			Day 3-6 – 5 mg/kg, 5 mg/kg, and 5 mg/kg
		3 injections (08:00,14:00, and 20:00)/day for 6 days	Day 1 – 1 mg/kg, 2 mg/kg, and 3 mg/kg	28 day	Wistar rat/Male	Disrupted latent inhibition	[12]
			Day 2 – 4 mg/kg, 5 mg/kg, and 5 mg/kg
			Day 3–6 – 5 mg/kg, 5 mg/kg, and 5 mg/kg
	Chronic and incremental dosage schedule	Once daily for day, 3 times (Monday, Wednesday, and Friday) for a week	Week 1 – 1 mg/kg	22 day	Sprague – Dawley rat/Male	Disrupted PPI and amphetamine sensitization (3 mg/kg challenge)	[2]
			Week 2 – 2 mg/kg
			Week 3 – 3 mg/kg
		Once daily, 3 times (Monday, Wednesday, and Friday) for a week	Week 1 – 1 mg/kg	22 day	Sprague – Dawley rat/Male	Disrupted PPI and amphetamine sensitization (3 mg/kg challenge)	[2]
			Week 2 – 2 mg/kg
			Week 3 – 3 mg/kg
			Week 4 – 4 mg/kg
			Week 5 – 5 mg/kg
Scopolamine	Acute schedule		0.15 and 0.5 mg/kg	<1 day	Wistar rat/Male	Disrupted latent inhibition	[3]
			0.3 and 0.5 mg/kg	<1 day	C57BL/6J mouse/Female	Social recognition deficit in 3-chamber test	[20]
			0.3, 1, 2, and 3 mg/kg	<1 day	CD-1 mouse/Male	Working memory deficit (T-maze spontaneous alteration)	[85]
			10 mg/kg	<1 day	C57BL/6NCrl mice/male	PPI impairment	[21]
Ketamine	Acute schedule		100 mg/kg	<1 day	Swiss mouse/Male	Hyperlocomotion and excessive fear (latency time of fear conditioning was increased)	[4]
	Sub-chronic schedule	Once daily for 5 days	10 mg/kg	21 day	Hooded Lister rat/Male	Working memory deficit	[35]
		Once daily for 5 days	30 mg/kg	10 day	Wistar rat/Male	Hyperlocomotion	[89]
		Once daily for 5 days	30 mg/kg	21 day	Hooded Lister rat/Male	Increased immobility time in forced swim test	[86]
		2 injection for 6 days	30 mg/kg	10 day	Long Evans rat/Male	Working memory deficit (Mismatch detection test)	[89]
	Chronic schedule	Once daily for 10 days	100 mg/kg	11 day	Swiss mouse/Male	Hyperlocomotion, increased immobility time in forced swim test, and increased latency time of fear conditioning	[4]
PCP	Acute schedule		5 mg/kg	<1 day	Sprague–Dawley rat	Hyperlocomotion	[32]
			2.58 mg/kg	<1 day	Long–Evans rats	Attentional set-shifting deficit (Extra dimensional shift)	[33]
			1.5 mg/kg	<1 day	C57Bl/6J mouse/Male	Hyperlocomotion, stereotype behavior, and reduced social interaction	[87]
			2 mg/kg	<1 day	C57Bl/6J mouse/Male	Hypolocomotion and reduced social interaction	[87]
			5 mg/kg	<1 day	C57BL/6J mice/Male	Hyperlocomotion	[5]
	Sub-chronic schedule	2 injection (0800 2000) for 7 days	5 mg/kg	10 day	Long-Evans rat	Attentional set-shifting deficit (Extra dimensional shift)	[34]
	Chronic schedule	Once daily for 10 days (days 1~5, 8~12)	5 mg/kg	<1 day	C57BL/6J mice/Male	Hyperlocomotion and disrupted working memory	[5]
LSD	Acute schedule		0.03, 0.1, and 0.3 mg/kg	<1 day	Wistar Rats/Male	Hyperlocomotion and disrupted PPI	[43]
	Acute schedule		0.1 and 0.3 mg/kg	<1 day	Sprague-Dawley Rats	Hyperlocomotion and disrupted PPI	[43]
	Chronic schedule	Once daily and every other day for 90 days	0.16 mg/kg	1 month	Sprague-Dawley rat/Male	Hyperlocomotion, decreased social behavior, and anhedonia	[6, 42]

^aPCP, phencyclidine; LSD, lysergic acid diethylamide; PPI, prepulse inhibition.

This table includes the drug, administration protocol, time taken behavioral experiments after administration of the drug, strain, and psychotic behaviors that was determined by each administration protocol. The administration protocol for 10 days or less was marked as a sub-chronic schedule, and administration protocol for over 10 days was marked as a chronic schedule. In the case of behavioral testing on the day of drug administration, it was labeled as occurring for less than 1 day.

Exp Neurobiol 2017;26:11~24 https://doi.org/10.5607/en.2017.26.1.11